This article is more than 5 years old. Information may no longer be current.

Cosentyx demonstrates efficacy in skin clearance for psoriasis over 4 years

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Novartis has announced that patients with moderate-to-severe plaque psoriasis maintained skin clearance after 4 years of treatment with Cosentyx, according to research presented at the European Academy of Dermatology and Venereology Congress in Vienna.

“[Study results] show that Cosentyx [secukinumab] keeps working year-on-year, maintaining high levels of skin clearance with a favorable safety profile,” Vasant Narashimhan, global head, Drug Development and chief medical officer of Novartis, stated in a press release. “Psoriasis patients need therapies they can use over long periods of time without loss of efficacy.”

In the research presented, Psoriasis Area Severity Index (PASI) 90 response of clear or almost clear skin was achieved by 68.5% of the patients in the study at year 1, with 66.4% of patients maintaining the response level at year 4. In year 1, 43.8% of patients achieved PASI 100 response of completely clear skin at year 1, and 43.5% maintained complete clearance at year 4. PASI 75 response was achieved 88.5% of patients at year 4, the release reported.

“The average improvement of psoriasis, as measured by PASI score was maintained at over 90% after 4 years of treatment,” according to the release.

A favorable safety profile was demonstrated during the study, which was consistent with previous phase 3 studies, according to the release.

Cosentyx, a fully human monoclonal antibody that selectively neutralizes IL-17A, is approved in the U.S. as treatment for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, as well treatment for active ankylosing spondylitis and psoriatic arthritis.

Reference: www.novartis.com

Bissonettte R, et al, Secukinumab maintains high levels of efficacy through 4 years of treatments: results from an extension to a phase 3 study (SCULPTURE). Late breaking abstract. Presented at: European Academy of Dermatology and Venereology Congress. Sept. 28-Oct. 2; Vienna.